Abstract
Abstract not available.
Highlights
Certolizumab pegol (CZP) has shown a safety profile consistent with the anti-tumor necrosis factor (TNF) class in adults with PSO over 96 weeks in phase 3 trials
We report cumulative safety data, pooled from three CZP in PSO phase 3 trials over 144 weeks, from a total of 995 patients
For patients exposed to both doses of CZP over the course of the studies, treatment-emergent adverse events (TEAEs) were assigned to the dose being received at the time of onset, but each patient was counted in the ‘analyzed for the dose-combined CZPtreated group (All CZP)’ group only once
Summary
CZP has shown a safety profile consistent with the anti-TNF class in adults with PSO over 96 weeks in phase 3 trials.3.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call